Nabriva Therapeutics Plc Revenue Growth Rates (NBRV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nabriva Therapeutics Plc  (NASDAQ: NBRV)
 

NBRV's Revenue Growth by Quarter and Year

Nabriva Therapeutics Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NBRV Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June 2.24
1st Quarter March 7.59
FY 9.83

NBRVs Annual Revenue
Nabriva Therapeutics Plc's Revenue in the fiscal year 2022 $ 36.94 millions
Nabriva Therapeutics Plc's Revenue in the fiscal year 2021 $ 28.90 millions
Nabriva Therapeutics Plc's Revenue in the fiscal year 2020 $ 5.03 millions
Nabriva Therapeutics Plc's Revenue in the fiscal year 2019 $ 9.48 millions
Nabriva Therapeutics Plc's Revenue in the fiscal year 2018 $ 9.66 millions




NBRV Revenue second quarter 2023 Y/Y Growth Comment
Nabriva Therapeutics Plc reported drop in Revenue in the second quarter 2023 by -75.59% to $ 2.24 millions, from the same quarter in 2022.
The fall in the second quarter 2023 Nabriva Therapeutics Plc's Revenue compares unfavorably to the Company's average Revenue doubling of 218.09%.

Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 237 other companies have achieved higher Revenue growth. While Nabriva Therapeutics Plc' s Revenue meltdown of -75.59% ranks overall at the positon no. 4015 in the second quarter 2023.


NBRV Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 14.15 % 276.42 % 645.45 %
3rd Quarter September - 3.27 % 586.82 % -81.36 %
2nd Quarter June -75.59 % 11.53 % 1581.63 % -7.55 %
1st Quarter March -5.36 % 217 % 220.25 % -53.53 %
FY   - 27.83 % 474.35 % -

Financial Statements
Nabriva Therapeutics Plc's second quarter 2023 Revenue $ 2.24 millions NBRV's Income Statement
Nabriva Therapeutics Plc's second quarter 2022 Revenue $ 9.19 millions Quarterly NBRV's Income Statement


NBRV Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 15.52 % 4.51 % 90.7 %
3rd Quarter September - -0.44 % 7.52 % 163.27 %
2nd Quarter June -70.45 % 14.59 % 225.69 % -37.97 %
1st Quarter March -28.19 % -13.39 % 2.85 % 139.39 %
FY (Year on Year)   - 27.83 % 474.35 % -


Back to NBRV Growth rate Comparisons >> Back to NBRV Growth rate Comparisons >>


Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #238
Healthcare Sector #616
Overall #4015

Revenue Y/Y Growth Statistics
High Average Low
1592.61 % 218.09 % -81.34 %
(Jun 30 2021)   (Sep 30 2020)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #238
Healthcare Sector #616
Overall #4015
Revenue Y/Y Growth Statistics
High Average Low
1592.61 % 218.09 % -81.34 %
(Jun 30 2021)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Nabriva Therapeutics Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1218.1 % 86.81 % -95.19 %
(Sep 30 2019)  


NBRV's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Nabriva Therapeutics Plc disclosed fall in Revenue from the first quarter by -70.45% to $ 2.24 millions, from $ 7.59 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 262 other companies have achieved higher Revenue quarter on quarter growth. While Nabriva Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 4180.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #263
Healthcare Sector #672
Overall #4180
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #263
Healthcare Sector #672
Overall #4180
Revenue Q/Q Growth Statistics
High Average Low
1218.1 % 86.81 % -95.19 %
(Sep 30 2019)  


NBRV's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Nabriva Therapeutics Plc disclosed fall in Revenue from the first quarter by -70.45% to $ 2.24 millions, from $ 7.59 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 262 other companies have achieved higher Revenue quarter on quarter growth. While Nabriva Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 4180.


Nabriva Therapeutics Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 29.56 $ 36.51 $ 36.94 $ 35.63 $ 35.33
Y / Y Revenue Growth (TTM) -16.35 % 6.16 % 27.82 % 61.24 % 143.3 %
Year on Year Revenue Growth Overall Ranking # 213 # 94 # 47 # 364 # 97
Seqeuential Revenue Change (TTM) -19.03 % -1.16 % 3.68 % 0.82 % 2.76 %
Seq. Revenue Growth (TTM) Overall Ranking # 2309 # 1174 # 798 # 1853 # 1025


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2023 Nabriva Therapeutics Plc reported a fall in Revenue by -16.35% year on year, to $30 millions, compare to the 6.16% growth at Mar 31 2023.

In the Healthcare sector 68 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 94 to 213.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 133
Healthcare Sector # 69
Overall # 213

Revenue TTM Y/Y Growth Statistics
High Average Low
661.86 %
 100.69 %
-70.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 133
Sector # 351
S&P 500 # 2309
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2023 Nabriva Therapeutics Plc reported a fall in Revenue by -16.35% year on year, to $30 millions, compare to the 6.16% growth at Mar 31 2023.

In the Healthcare sector 68 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 94 to 213.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 133
Healthcare Sector # 69
Overall # 213

Revenue TTM Y/Y Growth Statistics
High Average Low
661.86 %
100.69 %
-70.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 133
Sector # 351
S&P 500 # 2309




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NBRV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Fortrea Holdings Inc -0.01%$ -0.013 millions
Aquestive Therapeutics Inc -0.18%$ -0.181 millions
Phibro Animal Health Corporation-0.34%$ -0.340 millions
Procyon Corporation-0.59%$ -0.589 millions
Amedisys Inc-0.88%$ -0.882 millions
Baxter International Inc -1.04%$ -1.041 millions
Healthcare Services Group Inc -1.39%$ -1.395 millions
Bio rad Laboratories Inc -1.54%$ -1.536 millions
Harvard Bioscience Inc -1.83%$ -1.832 millions
Embecta Corp -1.92%$ -1.924 millions
Procaps Group S a -2.10%$ -2.102 millions
Enhabit Inc -2.13%$ -2.127 millions
Icu Medical Inc-2.26%$ -2.260 millions
Tandem Diabetes Care Inc -2.26%$ -2.261 millions
West Pharmaceutical Services Inc -2.27%$ -2.269 millions
Coherus Oncology inc -2.39%$ -2.386 millions
Hookipa Pharma inc -2.44%$ -2.440 millions
Biolife Solutions Inc -2.53%$ -2.529 millions
Enanta Pharmaceuticals Inc-3.01%$ -3.014 millions
Nrc Health-3.03%$ -3.033 millions
Intellia Therapeutics Inc -3.11%$ -3.108 millions
Organogenesis Holdings Inc -3.36%$ -3.365 millions
Omniab Inc -3.51%$ -3.514 millions
Marker Therapeutics inc -3.52%$ -3.523 millions
Akumin Inc -3.79%$ -3.793 millions
Endo International Plc-3.91%$ -3.912 millions
Integra Lifesciences Holdings Corp-4.16%$ -4.160 millions
Vireo Growth Inc.-4.24%$ -4.237 millions
Sonendo Inc -4.26%$ -4.257 millions
Avinger Inc -4.27%$ -4.268 millions


About Nabriva Therapeutics Plc Revenue Growth Rates (NBRV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nabriva Therapeutics Plc (CIK 1641640).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-23-016524
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nabriva Therapeutics Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.